BRPI0906838A2 - Pirimidinas como inibidores de quinase - Google Patents

Pirimidinas como inibidores de quinase

Info

Publication number: BRPI0906838A2
Authority: BR; Brazil
Prior art keywords: pyrimidines; kinase inhibitors; kinase; inhibitors
Prior art date: 2008-01-11

Application number

BRPI0906838-4A

Other languages

English (en)

Inventor

Peter Hunt

Catherine Leblanc

Robert Alexander Pulz

Nikolaus Johannes Stiefl

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-11

Filing date

2009-01-09

Publication date

2015-07-14

2009-01-09 Application filed by Novartis Ag filed Critical Novartis Ag

2015-07-14 Publication of BRPI0906838A2 publication Critical patent/BRPI0906838A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Virology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Biotechnology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)

BRPI0906838-4A 2008-01-11 2009-01-09 Pirimidinas como inibidores de quinase BRPI0906838A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08150194		2008-01-11
EP08157985		2008-06-10
PCT/EP2009/050222 WO2009087224A1 (en)	2008-01-11	2009-01-09	Pyrimidines as kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0906838A2 true BRPI0906838A2 (pt)	2015-07-14

Family

ID=40551454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906838-4A BRPI0906838A2 (pt)	2008-01-11	2009-01-09	Pirimidinas como inibidores de quinase

Country Status (14)

Country	Link
US (1)	US8431578B2 (pt)
EP (1)	EP2231642B1 (pt)
JP (1)	JP5584138B2 (pt)
KR (1)	KR20100113557A (pt)
CN (1)	CN101910153B (pt)
AU (1)	AU2009203693B2 (pt)
BR (1)	BRPI0906838A2 (pt)
CA (1)	CA2711637A1 (pt)
EA (1)	EA201001129A1 (pt)
ES (1)	ES2442930T3 (pt)
MX (1)	MX2010007604A (pt)
PL (1)	PL2231642T3 (pt)
PT (1)	PT2231642E (pt)
WO (1)	WO2009087224A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012002577A1 (ja)	2010-06-30	2012-01-05	富士フイルム株式会社	新規なニコチンアミド誘導体またはその塩
JP5886842B2 (ja) *	2010-07-05	2016-03-16	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	キナーゼ誘発疾患の処置に有用なビピリジル誘導体
CN103124496B (zh)	2010-10-06	2016-03-30	葛兰素史密丝克莱恩有限责任公司	作为pi3激酶抑制剂的苯并咪唑衍生物
GB201112607D0 (en)	2011-07-22	2011-09-07	Glaxo Group Ltd	Novel compounds
EP2592154A1 (en)	2011-11-09	2013-05-15	Cellzome Ag	Immobilization products and methods for the identification of histone demethylase interacting molecules and for the purification of histone demethylase proteins
JO3407B1 (ar)	2012-05-31	2019-10-20	Eisai R&D Man Co Ltd	مركبات رباعي هيدرو بيرازولو بيريميدين
US9682983B2 (en)	2013-03-14	2017-06-20	The Brigham And Women's Hospital, Inc.	BMP inhibitors and methods of use thereof
EP3122355A4 (en) *	2014-03-26	2017-08-09	The Brigham and Women's Hospital, Inc.	Compositions and methods for inhibiting bmp
US10513521B2 (en)	2014-07-15	2019-12-24	The Brigham And Women's Hospital, Inc.	Compositions and methods for inhibiting BMP
AU2018367909B2 (en)	2017-11-17	2022-03-10	Cellix Bio Private Limited	Compositions and methods for the treatment of eye disorders
BR112020012651A2 (pt) *	2017-12-22	2020-12-01	Ravenna Pharmaceuticals, Inc.	compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
WO2022013307A1 (en)	2020-07-15	2022-01-20	Chiesi Farmaceutici S.P.A.	Pyridazinyl amino derivatives as alk5 inhibitors
EP4182322B1 (en)	2020-07-15	2024-04-24	Chiesi Farmaceutici S.p.A.	Pyrido oxazine derivatives as alk5 inhibitors
MX2023000519A (es)	2020-07-15	2023-02-13	Chiesi Farm Spa	Derivados de pirido-oxazina-amino como inhibidores de alk5.
WO2022136221A1 (en)	2020-12-23	2022-06-30	Chiesi Farmaceutici S.P.A.	Pyrido oxazine derivatives as alk5 inhibitors
CA3232178A1 (en)	2021-09-21	2023-03-30	Daniela PIZZIRANI	Pyridazinyl amino derivatives as alk5 inhibitors
JP2025504402A (ja) *	2022-01-11	2025-02-12	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	Ａｌｋ５阻害剤としてのピリダジニルアミノ誘導体
WO2023208986A1 (en)	2022-04-27	2023-11-02	Chiesi Farmaceutici S.P.A.	Imidazole derivatives as alk5 inhibitors

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1219606A (en)	1968-07-15	1971-01-20	Rech S Et D Applic Scient Soge	Quinuclidinol derivatives and preparation thereof
IT1016489B (it)	1974-03-18	1977-05-30	Isf Spa	Inalatore
GB8334494D0 (en)	1983-12-24	1984-02-01	Tanabe Seiyaku Co	Carbostyril derivatives
JPS6235216A (ja)	1985-08-09	1987-02-16	Noritoshi Nakabachi	不均質物質層の層厚非破壊測定方法および装置
GB8916480D0 (en)	1989-07-19	1989-09-06	Glaxo Group Ltd	Chemical process
GB8923590D0 (en)	1989-10-19	1989-12-06	Pfizer Ltd	Antimuscarinic bronchodilators
DE3940477A1 (de) *	1989-12-07	1991-06-13	Bayer Ag	Hetaryl-substituierte pyridinylpyrimidin-derivate
JP2864725B2 (ja)	1990-11-20	1999-03-08	ソニー株式会社	画像信号の高能率符号化装置
PT100441A (pt)	1991-05-02	1993-09-30	Smithkline Beecham Corp	Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5451700A (en)	1991-06-11	1995-09-19	Ciba-Geigy Corporation	Amidino compounds, their manufacture and methods of treatment
WO1993018007A1 (fr)	1992-03-13	1993-09-16	Tokyo Tanabe Company Limited	Nouveau derive de carbostyrile
CZ283425B6 (cs)	1992-04-02	1998-04-15	Smithkline Beecham Corporation	Fenylové deriváty a farmaceutické prostředky s jejich obsahem
AU3924993A (en)	1992-04-02	1993-11-08	Smithkline Beecham Corporation	Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
JP3192424B2 (ja)	1992-04-02	2001-07-30	スミスクライン・ビーチャム・コーポレイション	アレルギーまたは炎症疾患の治療用化合物
GB9301000D0 (en)	1993-01-20	1993-03-10	Glaxo Group Ltd	Chemical compounds
US6596260B1 (en)	1993-08-27	2003-07-22	Novartis Corporation	Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
GB9414208D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
GB9414193D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
DK0995457T3 (da)	1995-12-07	2004-08-16	Jago Res Ag	Mundstykke til inhalator til flere dosisvise afgivelser af farmakologisk törpulver
DE69712324T2 (de)	1996-02-21	2002-08-29	Schering Corp., Kenilworth	Inhalator für pulverartiges medikament
GB9622386D0 (en)	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
TW528755B (en)	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO1999016766A1 (en)	1997-10-01	1999-04-08	Kyowa Hakko Kogyo Co., Ltd.	Benzodioxole derivatives
GB9723590D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
GB9723566D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
GB9723589D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
YU44900A (sh)	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es)	1998-02-14	2001-09-05	Glaxo Group Ltd	Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
AP2000002016A0 (en)	1998-06-23	2000-12-31	Glaxo Group Ltd	2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813565D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
DE69827673T2 (de)	1998-06-30	2005-04-21	Dow Global Technologies Inc	Polymerpolyole und ein verfahren zu ihrer darstellung
BR9914526A (pt)	1998-10-16	2001-07-03	Pfizer	Derivados de adenina
GB9913083D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
YU25500A (sh)	1999-05-11	2003-08-29	Pfizer Products Inc.	Postupak za sintezu analoga nukleozida
US6683115B2 (en)	1999-06-02	2004-01-27	Theravance, Inc.	β2-adrenergic receptor agonists
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1671651B1 (en)	1999-08-21	2009-11-11	Nycomed GmbH	Synergistic combination of pumafentrine and salmeterol
CO5180581A1 (es)	1999-09-30	2002-07-30	Pfizer Prod Inc	Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924363D0 (en)	1999-10-14	1999-12-15	Pfizer Central Res	Purine derivatives
GB9924361D0 (en)	1999-10-14	1999-12-15	Pfizer Ltd	Purine derivatives
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
AU5629301A (en)	2000-04-27	2001-11-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Novel, slow-acting betamimetics, a method for their production and their use as medicaments
TWI227240B (en)	2000-06-06	2005-02-01	Pfizer	2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en)	2000-06-27	2000-08-16	Pfizer Ltd	Purine derivatives
UA72632C2 (uk)	2000-06-27	2005-03-15	Лабораторіос С.А.Л.В.А.Т., С.А.	Карбамати, похідні від арилалкіламінів
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
DE10038639A1 (de)	2000-07-28	2002-02-21	Schering Ag	Nichtsteroidale Entzündungshemmer
WO2002012265A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY&excl;-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
GB0028383D0 (en)	2000-11-21	2001-01-03	Novartis Ag	Organic compounds
AU2002228015B2 (en)	2000-12-22	2007-08-23	Almirall, S.A.	Quinuclidine carbamate derivatives and their use as M3 antagonists
UA75626C2 (en)	2000-12-28	2006-05-15	Almirall Prodesfarma Ag	Quinuclidine derivatives and medicinal compositions containing the same
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
US7144908B2 (en)	2001-03-08	2006-12-05	Glaxo Group Limited	Agonists of beta-adrenoceptors
EP1241176A1 (en)	2001-03-16	2002-09-18	Pfizer Products Inc.	Purine derivatives for the treatment of ischemia
ES2296923T3 (es)	2001-03-22	2008-05-01	Glaxo Group Limited	Derivados formanilidas como agonistas del adrenorreceptor beta2.
US7291608B2 (en)	2001-04-30	2007-11-06	Glaxo Group Limited	Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
WO2002096462A1 (en)	2001-05-25	2002-12-05	Pfizer Inc.	An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
JP2005500290A (ja)	2001-06-12	2005-01-06	グラクソ　グループ　リミテッド	抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
JP4405258B2 (ja)	2001-06-21	2010-01-27	ヴェレニウムコーポレイション	ニトリラーゼ
ATE417606T1 (de)	2001-09-14	2009-01-15	Glaxo Group Ltd	Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
WO2003027085A2 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
KR20050030169A (ko)	2001-10-17	2005-03-29	유씨비 소시에떼아노님	퀴누클리딘 유도체, 이의 제조 방법 및 ｍ2 및/또는 ｍ3무스카린 수용체 억제제로서의 이의 용도
MY130622A (en)	2001-11-05	2007-07-31	Novartis Ag	Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
HU229504B1 (hu)	2001-11-09	2014-01-28	Gilead Sciences	A2B-adenozinreceptor-antagonisták
WO2003042160A1 (en)	2001-11-13	2003-05-22	Theravance, Inc.	Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en)	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
UA76571C2 (en)	2001-12-20	2006-08-15		Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
CA2477764A1 (en)	2002-03-26	2003-10-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PL373043A1 (en)	2002-03-26	2005-08-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20090170803A1 (en)	2002-04-10	2009-07-02	Linden Joel M	Adjunctive treatment of biological diseases
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
JP2005523920A (ja)	2002-04-25	2005-08-11	グラクソ　グループ　リミテッド	フェネタノールアミン誘導体
WO2003099764A1 (en)	2002-05-28	2003-12-04	Theravance, Inc.	ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
ES2201907B1 (es)	2002-05-29	2005-06-01	Almirall Prodesfarma, S.A.	Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de)	2002-06-05	2003-12-24	Merck Patent Gmbh	Pyridazinderivate
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de)	2002-06-10	2003-12-18	Merck Patent Gmbh	Aryloxime
DE10227269A1 (de)	2002-06-19	2004-01-08	Merck Patent Gmbh	Thiazolderivate
EP1517895B1 (en)	2002-06-25	2007-03-14	Merck Frosst Canada Ltd.	8-(biaryl) quinoline pde4 inhibitors
ES2204295B1 (es)	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
JP2005538972A (ja)	2002-07-02	2005-12-22	メルクフロストカナダアンドカンパニー	ジアリール置換エタンピリドンｐｄｅ４阻害剤
MXPA05000345A (es)	2002-07-08	2005-03-31	Pfizer Prod Inc	Moduladores del receptor de glucocorticoides.
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
JP2005539000A (ja) *	2002-07-31	2005-12-22	スミスクライン・ビーチャム・コーポレイション	Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
GB0217786D0 (en) *	2002-07-31	2002-09-11	Glaxo Group Ltd	Compounds
PE20050130A1 (es)	2002-08-09	2005-03-29	Novartis Ag	Compuestos organicos
AU2003255376A1 (en)	2002-08-10	2004-03-11	Altana Pharma Ag	Piperidine-derivatives as pde4 inhibitors
EP1556369A1 (en)	2002-08-10	2005-07-27	ALTANA Pharma AG	Pyridazinone-derivatives as pde4 inhibitors
HRP20050197A2 (en)	2002-08-10	2006-06-30	Altana Pharma Ag	Piperidine-n-oxide-derivatives
CA2494613C (en)	2002-08-10	2011-06-28	Altana Pharma Ag	Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
EP1581533A2 (en)	2002-08-17	2005-10-05	ALTANA Pharma AG	Novel benzonaphthyridines
RS20050116A (sr)	2002-08-17	2007-11-15	Altana Pharma Ag.,	Novi fenantridini
DE60231341D1 (de)	2002-08-23	2009-04-09	Ranbaxy Lab Ltd	Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
ATE348616T1 (de)	2002-08-29	2007-01-15	Altana Pharma Ag	2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
JP4587295B2 (ja)	2002-08-29	2010-11-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	Ｐｄｅ４インヒビターとしての３−ヒドロキシ−６−フェニルフェナントリジン
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
JP2006096662A (ja)	2002-09-18	2006-04-13	Sumitomo Pharmaceut Co Ltd	新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja)	2002-09-20	2004-04-08	Japan Energy Corp	新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE10246374A1 (de)	2002-10-04	2004-04-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2499314C (en)	2002-10-11	2010-08-24	Pfizer Inc.	Indole derivatives as beta-2 agonists
EP1440966A1 (en)	2003-01-10	2004-07-28	Pfizer Limited	Indole derivatives useful for the treatment of diseases
ES2291733T3 (es)	2002-10-22	2008-03-01	Glaxo Group Limited	Compuestos de ariletanolamina medicinales.
ATE380185T1 (de)	2002-10-23	2007-12-15	Glenmark Pharmaceuticals Ltd	Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
DK1556342T3 (da)	2002-10-28	2008-07-21	Glaxo Group Ltd	Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
DE10253282A1 (de)	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253426B4 (de)	2002-11-15	2005-09-22	Elbion Ag	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de)	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
NZ541232A (en)	2003-01-09	2008-02-29	Astellas Pharma Inc	Pyrrolopyridazine derivatives
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (en)	2003-03-14	2004-09-22	Pfizer Limited	Indole-2-carboxamide derivatives useful as beta-2 agonists
JP4767842B2 (ja)	2003-04-01	2011-09-07	セラヴァンス，インコーポレーテッド	β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
EP1613315B1 (en)	2003-04-04	2009-01-21	Novartis AG	Quinoline-2-one-derivatives for the treatment of airways diseases
AR044134A1 (es)	2003-05-02	2005-08-24	Novartis Ag	Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
US7268147B2 (en)	2003-05-15	2007-09-11	Pfizer Inc	Compounds useful for the treatment of diseases
EP1477167A1 (en)	2003-05-15	2004-11-17	Pfizer Limited	[(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
ES2329133T3 (es)	2003-05-28	2009-11-23	Theravance, Inc.	Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
GB0312832D0 (en)	2003-06-04	2003-07-09	Pfizer Ltd	2-amino-pyridine derivatives useful for the treatment of diseases
ATE384697T1 (de)	2003-06-04	2008-02-15	Pfizer	2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
JP2006527207A (ja)	2003-06-11	2006-11-30	メルクフロストカナダリミテツド	７−（１，３−チアゾール−２−イル）チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用
WO2004111044A1 (en)	2003-06-17	2004-12-23	Glenmark Pharmaceuticals Ltd.	Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
ITMI20031451A1 (it)	2003-07-16	2005-01-17	Zambon Spa	Derivati diidro-ftalazinici inibitori della fosfodiesterasi 4
JP2007500685A (ja)	2003-07-31	2007-01-18	アルタナ　ファルマ　アクチエンゲゼルシャフト	新規の６−フェニルフェナントリジン
JP2007500686A (ja)	2003-07-31	2007-01-18	アルタナ　ファルマ　アクチエンゲゼルシャフト	新規の６−フェニルフェナントリジン
US20050059567A1 (en)	2003-09-11	2005-03-17	The Procter & Gamble Company	Methods of formulating enzyme cocktails, enzyme cocktails for the removal of egg-based and grass-based stains and/or soils, compositions and products comprising same
GB0322722D0 (en)	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds
GB0322726D0 (en)	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds
WO2005033121A2 (en)	2003-10-03	2005-04-14	King Pharmaceuticals Research & Development, Inc.	Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
GB0323701D0 (en)	2003-10-09	2003-11-12	Glaxo Group Ltd	Formulations
GB2407042B (en)	2003-10-17	2007-10-24	Vectura Ltd	Inhaler
GB0324654D0 (en)	2003-10-22	2003-11-26	Glaxo Group Ltd	Medicinal compounds
GB0324886D0 (en)	2003-10-24	2003-11-26	Glaxo Group Ltd	Medicinal compounds
GB0329182D0 (en)	2003-12-17	2004-01-21	Glaxo Group Ltd	Chemical compounds
US8506794B2 (en)	2003-12-19	2013-08-13	Shell Oil Company	Systems, methods, and catalysts for producing a crude product
JP2005187357A (ja)	2003-12-25	2005-07-14	Nippon Suisan Kaisha Ltd	選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
DE102004001413A1 (de)	2004-01-09	2005-08-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
ES2289691T3 (es)	2004-01-22	2008-02-01	Pfizer, Inc.	Derivados de sulfonamida para el tratamiento de enfermedades.
OA13362A (en)	2004-01-22	2007-04-13	Pfizer	Sulfonamide derivatives for the treatment of diseases.
DE102004003428A1 (de)	2004-01-23	2005-08-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
GB0402797D0 (en)	2004-02-09	2004-03-10	Novartis Ag	Organic compounds
WO2005080375A1 (en)	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
WO2005077361A1 (de)	2004-02-14	2005-08-25	Boehringer Ingelheim International Gmbh	Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
AU2005221832A1 (en)	2004-03-10	2005-09-22	Nycomed Gmbh	Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
CA2558390A1 (en)	2004-03-10	2005-09-22	Altana Pharma Ag	Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
EP1574501A1 (en)	2004-03-11	2005-09-14	Pfizer Limited	Quinolinone derivatives, pharmaceutical compositions containing them and their use
JPWO2005087749A1 (ja)	2004-03-15	2007-08-09	協和醗酵工業株式会社	２−アミノキナゾリン誘導体
EP1577292A1 (en)	2004-03-17	2005-09-21	Pfizer Limited	Phenylaminoethanol derivatives as beta2 receptor agonists
US7244728B2 (en)	2004-03-17	2007-07-17	Boehringer Ingelheim International Gmbh	Long acting betamimetics for the treatment of respiratory diseases
BRPI0508927A (pt)	2004-03-17	2007-08-14	Pfizer	compostos úteis para o tratamento de doenças
US7671068B2 (en)	2004-03-17	2010-03-02	Nycomed Gmbh	N-(alkoxyalkyl) carbamoyl-substituted 6-phenyl-benzonaphthyridine derivatives and their use as PDE ¾ inhibitors
JP4108117B2 (ja)	2004-03-23	2008-06-25	ファイザー・インク	疾患を処置するための化合物
US20050215542A1 (en)	2004-03-23	2005-09-29	Pfizer Inc	Compounds for the treatment of diseases
WO2005092860A1 (en)	2004-03-23	2005-10-06	Pfizer Limited	Compounds for the treatment of diseases
PL1730103T3 (pl)	2004-03-23	2010-10-29	Pfizer	Pochodne formamidu użyteczne jako adrenoreceptor
AU2005227733A1 (en)	2004-04-02	2005-10-13	Glaxo Group Limited	Chemical process and new crystalline form
DE602005024382D1 (de) *	2004-04-13	2010-12-09	Astellas Pharma Inc	Polycyclische pyrimidine als kaliumionenkanal-modulatoren
DE102004019539A1 (de)	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US20050239778A1 (en)	2004-04-22	2005-10-27	Boehringer Ingelheim International Gmbh	Novel medicament combinations for the treatment of respiratory diseases
KR20070004963A (ko)	2004-04-29	2007-01-09	시바 스폐셜티 케미칼스 홀딩 인코포레이티드	경질 표면 상의 착색 얼룩을 표백하기 위한 퍼옥시화합물과의 반응에 대한 촉매로서 비스피리딜피리미딘 또는비스피리딜트리아진 리간드를 갖는 금속 착물의 용도
GB0410712D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
US7307076B2 (en)	2004-05-13	2007-12-11	Boehringer Ingelheim International Gmbh	Beta agonists for the treatment of respiratory diseases
US20050256115A1 (en)	2004-05-14	2005-11-17	Boehringer Ingelheim International Gmbh	Aerosol formulation for the inhalation of beta-agonists
WO2005121065A2 (en)	2004-06-03	2005-12-22	Theravance, Inc.	DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
JP2008507532A (ja)	2004-07-21	2008-03-13	セラヴァンス，インコーポレーテッド	ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
GB0416397D0 (en)	2004-07-22	2004-08-25	Glaxo Group Ltd	Pharmaceutical formulations
EP1786802A1 (en) *	2004-08-31	2007-05-23	Biogen Idec MA, Inc.	Pyrimidinylimidazoles as tgf-beta inhibitors
US7566785B2 (en)	2004-09-10	2009-07-28	Theravance, Inc.	Amidine substituted aryl aniline compounds
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
CN101137625A (zh)	2005-01-11	2008-03-05	葛兰素集团有限公司	β2肾上腺素能激动剂的肉桂酸盐
EP2001849B1 (en) *	2006-03-29	2014-11-26	F. Hoffmann-La Roche AG	Pyridine and pyrimidine derivatives as mglur2 antagonists
CA2657227A1 (en)	2006-07-14	2008-01-17	Novartis Ag	Pyrimidine derivatives as alk-5 inhibitors
US8012986B2 (en) *	2007-04-02	2011-09-06	Hoffmann-La Roche Inc.	Pyridine and pyrimidine derivatives as MGLUR2 antagonists

2009
- 2009-01-09 JP JP2010541793A patent/JP5584138B2/ja not_active Expired - Fee Related
- 2009-01-09 US US12/810,948 patent/US8431578B2/en not_active Expired - Fee Related
- 2009-01-09 ES ES09700452.7T patent/ES2442930T3/es active Active
- 2009-01-09 EP EP09700452.7A patent/EP2231642B1/en not_active Not-in-force
- 2009-01-09 KR KR1020107017742A patent/KR20100113557A/ko not_active Withdrawn
- 2009-01-09 CN CN200980101839.1A patent/CN101910153B/zh not_active Expired - Fee Related
- 2009-01-09 WO PCT/EP2009/050222 patent/WO2009087224A1/en not_active Ceased
- 2009-01-09 AU AU2009203693A patent/AU2009203693B2/en not_active Ceased
- 2009-01-09 BR BRPI0906838-4A patent/BRPI0906838A2/pt not_active IP Right Cessation
- 2009-01-09 CA CA2711637A patent/CA2711637A1/en not_active Abandoned
- 2009-01-09 MX MX2010007604A patent/MX2010007604A/es active IP Right Grant
- 2009-01-09 EA EA201001129A patent/EA201001129A1/ru unknown
- 2009-01-09 PL PL09700452T patent/PL2231642T3/pl unknown
- 2009-01-09 PT PT97004527T patent/PT2231642E/pt unknown

Also Published As

Publication number	Publication date
PT2231642E (pt)	2014-03-12
KR20100113557A (ko)	2010-10-21
EP2231642B1 (en)	2013-10-23
AU2009203693B2 (en)	2012-06-07
EA201001129A1 (ru)	2011-02-28
ES2442930T3 (es)	2014-02-14
US20100298337A1 (en)	2010-11-25
PL2231642T3 (pl)	2014-04-30
US8431578B2 (en)	2013-04-30
EP2231642A1 (en)	2010-09-29
WO2009087224A1 (en)	2009-07-16
CN101910153A (zh)	2010-12-08
CA2711637A1 (en)	2009-07-16
MX2010007604A (es)	2010-08-02
JP2011509278A (ja)	2011-03-24
AU2009203693A1 (en)	2009-07-16
CN101910153B (zh)	2014-01-22
JP5584138B2 (ja)	2014-09-03

Publication	Publication Date	Title
FR25C1006I1 (fr)	2025-04-04	Inhibiteurs de pyrazolyl-quinoxaline kinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
CY2019027I2 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
BRPI0908494A2 (pt)	2015-08-11	Inibidores de pirrolopirazina quinase
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
EP2498607A4 (en)	2013-06-19	Kinase Inhibitors
EP2493313A4 (en)	2013-05-15	Kinase Inhibitors
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
BRPI0906973A2 (pt)	2015-07-14	Compostos e composições como inibidores de cinase.
BRPI0912475A8 (pt)	2018-03-20	compostos como inibidores de quinase
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0809974A2 (pt)	2014-10-07	Compostos de pirimidina hidrazida como inibidores de pgds
BRPI0907435A2 (pt)	2015-07-14	Derivados de 5-flúor pirimidina
EP2558099A4 (en)	2013-07-17	Kinase inhibitors
EP2632898A4 (en)	2014-04-02	HETEROCYCLIC TYROSINE KINASE HEMMER
BRPI0812825A2 (pt)	2014-12-09	Derivados ftalazinona como inibidores de parp-1
BRPI1009112A2 (pt)	2016-03-01	inibidores de tirosina quinase de bruton
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BR112012004843A2 (pt)	2019-09-24	compostos como moduladores de tirosina cinase
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.